EUVIMEDEUVIMED entdecken
Crossref

Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1670f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca – Lilly) has received accelerated approval from the FDA for treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults who received ≥2 prior lines of systemic therapy, including a BTK inhibitor. Accelerated approval was based on the response rate. The BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) are also approved for treatment of MCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAdultHumansTyrosine Kinase InhibitorsPyrazoles

Stichwörter der Autor:innen

BrukinsaCalquenceImbruvicaJaypircaacalabrutinibadverse effectsdosagedrug interactionsefficacyibrutiniblactationlymphomapirtobrutinibpregnancysafety

Substanzen

Tyrosine Kinase InhibitorspirtobrutinibPyrazoles

Zitieren

APA

(2023). Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670f

Vancouver

Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670f

BibTeX
@article{euvimed2023,
  title = {Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1670f}
}
Kostenlos starten →